240 related articles for article (PubMed ID: 31060404)
1. Fabrication, optimization, and
Mathur P; Sharma S; Rawal S; Patel B; Patel MM
J Liposome Res; 2020 Jun; 30(2):182-196. PubMed ID: 31060404
[TBL] [Abstract][Full Text] [Related]
2. An industrially viable technique for fabrication of docetaxel NLCs for oncotherapy.
Kharkar PB; Talkar SS; Patravale VB
Int J Pharm; 2020 Mar; 577():119082. PubMed ID: 31988031
[TBL] [Abstract][Full Text] [Related]
3. Process, optimization, and characterization of budesonide-loaded nanostructured lipid carriers for the treatment of inflammatory bowel disease.
Sinhmar GK; Shah NN; Chokshi NV; Khatri HN; Patel MM
Drug Dev Ind Pharm; 2018 Jul; 44(7):1078-1089. PubMed ID: 29376433
[TBL] [Abstract][Full Text] [Related]
4. Enhanced docetaxel delivery using sterically stabilized RIPL peptide-conjugated nanostructured lipid carriers: In vitro and in vivo antitumor efficacy against SKOV3 ovarian cancer cells.
Kim CH; Kang TH; Kim BD; Lee TH; Yoon HY; Goo YT; Choi YS; Kang MJ; Choi YW
Int J Pharm; 2020 Jun; 583():119393. PubMed ID: 32376445
[TBL] [Abstract][Full Text] [Related]
5. Formulation, optimization, and characterization of rifampicin-loaded solid lipid nanoparticles for the treatment of tuberculosis.
Chokshi NV; Khatri HN; Patel MM
Drug Dev Ind Pharm; 2018 Dec; 44(12):1975-1989. PubMed ID: 30058392
[TBL] [Abstract][Full Text] [Related]
6. Fabrication, optimisation and
Rawal S; Patel B; Patel MM
J Microencapsul; 2020 Dec; 37(8):543-556. PubMed ID: 32924677
[TBL] [Abstract][Full Text] [Related]
7. RIPL peptide-conjugated nanostructured lipid carriers for enhanced intracellular drug delivery to hepsin-expressing cancer cells.
Lee SG; Kim CH; Sung SW; Lee ES; Goh MS; Yoon HY; Kang MJ; Lee S; Choi YW
Int J Nanomedicine; 2018; 13():3263-3278. PubMed ID: 29910614
[TBL] [Abstract][Full Text] [Related]
8. Targeted Nanostructured Lipid Carrier for Brain Delivery of Artemisinin: Design, Preparation, Characterization, Optimization and Cell Toxicity.
Emami J; Yousefian H; Sadeghi H
J Pharm Pharm Sci; 2018; 21(1s):225s-241s. PubMed ID: 30266137
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol loaded functionalized nanostructured lipid carriers for breast cancer targeting: Systematic development, characterization and pharmacokinetic evaluation.
Poonia N; Kaur Narang J; Lather V; Beg S; Sharma T; Singh B; Pandita D
Colloids Surf B Biointerfaces; 2019 Sep; 181():756-766. PubMed ID: 31234063
[TBL] [Abstract][Full Text] [Related]
10. Development of self-assembled nanocarriers to enhance antitumor efficacy of docetaxel trihydrate in MDA-MB-231 cell line.
Rarokar NR; Khedekar PB; Bharne AP; Umekar MJ
Int J Biol Macromol; 2019 Mar; 125():1056-1068. PubMed ID: 30572051
[TBL] [Abstract][Full Text] [Related]
11. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel.
Liu D; Liu Z; Wang L; Zhang C; Zhang N
Colloids Surf B Biointerfaces; 2011 Jul; 85(2):262-9. PubMed ID: 21435845
[TBL] [Abstract][Full Text] [Related]
12. Systematic implementation of quality-by-design (QbD) to develop NSAID-loaded nanostructured lipid carriers for ocular application: preformulation screening studies and statistical hybrid-design for optimization of variables.
Rathod VR; Shah DA; Dave RH
Drug Dev Ind Pharm; 2020 Mar; 46(3):443-455. PubMed ID: 32037896
[TBL] [Abstract][Full Text] [Related]
13. Improved chemotherapeutic efficacy against resistant human breast cancer cells with co-delivery of Docetaxel and Thymoquinone by Chitosan grafted lipid nanocapsules: Formulation optimization, in vitro and in vivo studies.
Zafar S; Akhter S; Ahmad I; Hafeez Z; Alam Rizvi MM; Jain GK; Ahmad FJ
Colloids Surf B Biointerfaces; 2020 Feb; 186():110603. PubMed ID: 31846892
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of etoposide to cancer cells by folate-modified nanostructured lipid drug delivery system.
Zhang S; Lu C; Zhang X; Li J; Jiang H
Drug Deliv; 2016 Jun; 23(5):1838-45. PubMed ID: 26879035
[TBL] [Abstract][Full Text] [Related]
15. Targeted Nanostructured Lipid Carriers for Delivery of Paclitaxel to Cancer Cells: Preparation, Characterization, and Cell Toxicity.
Rezazadeh M; Emami J; Hassanzadeh F; Sadeghi H; Rostami M; Mohammadkhani H
Curr Drug Deliv; 2017; 14(8):1189-1200. PubMed ID: 28472908
[TBL] [Abstract][Full Text] [Related]
16. Lung cancer combination therapy: doxorubicin and β-elemene co-loaded, pH-sensitive nanostructured lipid carriers.
Cao C; Wang Q; Liu Y
Drug Des Devel Ther; 2019; 13():1087-1098. PubMed ID: 31118562
[No Abstract] [Full Text] [Related]
17. Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro, ex vivo and in vivo assessments.
Soni K; Rizwanullah M; Kohli K
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):15-31. PubMed ID: 29183147
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel-loaded ultrasmall nanostructured lipid carriers for cancer therapy: in vitro and in vivo evaluation.
Li M; Pei J; Ma Z; Fu J; Chen F; Du S
Cancer Chemother Pharmacol; 2020 Apr; 85(4):731-739. PubMed ID: 32146495
[TBL] [Abstract][Full Text] [Related]
19. Box-Behnken study design for optimization of bicalutamide-loaded nanostructured lipid carrier: stability assessment.
Kudarha R; Dhas NL; Pandey A; Belgamwar VS; Ige PP
Pharm Dev Technol; 2015; 20(5):608-18. PubMed ID: 24785784
[TBL] [Abstract][Full Text] [Related]
20. In vitro characterization and growth inhibition effect of nanostructured lipid carriers for controlled delivery of methotrexate.
Abdelbary G; Haider M
Pharm Dev Technol; 2013; 18(5):1159-68. PubMed ID: 21958084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
